AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26552423
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment only
Trial: 24217275
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care treatment (CG)
Trial: 10445535
Drug: Serial IgG
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial IgG antibody determinations
Trial: 10445535
Drug: Parallel IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel IgG antibody determinations
Trial: 465432
Drug: Iron fortification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron fortification of food providing 10 mg elemental Fe/child per day
Trial: 465432
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (5 mg) mixed in one meal
Trial: 465432
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (3.3 mg) given with each of three meals over 2 days
Trial: 465432
Drug: Ferrous ascorbate
RxNorm normalized name: Ferrous ascorbate
DrugBank: Ferrous ascorbate (DB14490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous ascorbate (test dose)
Trial: 29096672
Drug: Yoga (90-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga (90-min session weekly for 8 weeks)
Trial: 29096672
Drug: Stretching and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching and resistance exercises (60-min session weekly for 8 weeks)
Trial: 19772596
Drug: Structured weekly
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured weekly SMS messaging
Trial: 17963859
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills (OCs) initiation
Trial: 2617244
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg i.v.
Trial: 22284315
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with tramadol (1.0 mg/kg loading dose, 10 mg metoclopramide, 0.3 mg/kg/mL every 5 minutes)
Trial: 22284315
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with remifentanil (placebo 100 mL 0.9% normal saline, 0.4 μg/kg/mL every two minutes)
Trial: 16285948
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (17 to 23 mg/kg body weight per day)
Trial: 11929950
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy with sequentially added progestins (HRTsp)
Trial: 11929950
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy with continuously added progestins (HRTcp)
Trial: 11929950
Drug: Low-potency estrogens
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-potency estrogens (oral)
Trial: 7638806
Drug: All modes
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All modes of inhalation studied
Trial: 2572036
Drug: Broxaterol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol (oral route, total dose 1.675 mg)
Trial: 2572036
Drug: Broxaterol (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol (inhaled route, total dose 1.5 mg)
Trial: 2572036
Drug: Salbutamol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (oral route, total dose 26 mg)
Trial: 2572036
Drug: Salbutamol (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (inhaled route, total dose 1.5 mg)
Trial: 2572036
Drug: Broxaterol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol (oral route)
Trial: 2572036
Drug: Broxaterol (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol (inhaled route)
Trial: 31843335
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate plus androgen deprivation therapy (AAP + ADT)
Trial: 31843335
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus androgen deprivation therapy (PBO + ADT)
Trial: 28121978
Drug: Topical Lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Lidocaine cream (TL)
Trial: 27561376
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch (applied from 3 days before to 7 days after surgery)
Trial: 27561376
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rivastigmine patch)
Trial: 21645184
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch
Trial: 18397386
Drug: Ribavirin 800
RxNorm normalized name: ribavirin 800 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 800 mg/day
Trial: 18397386
Drug: Ribavirin 1000/1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 1000/1200 mg/day
Trial: 12669750
Drug: Preparation time
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation time in go trials
Trial: 11127213
Drug: HRT (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (2 mg of estradiol valerate and 1 mg of cyproterone acetate with or without vitamin D3, 100-300 IU + 93 mg calcium as lactate per day)
Trial: 11127213
Drug: Non-HRT (93
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-HRT (93 mg of calcium alone or in combination with vitamin D3, 100-300 IU/day)
Trial: 9192993
Drug: Prophylactic intracavitary
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intracavitary treatment with interferon alpha 2b (IFN‐alpha‐2b)
Trial: 22256639
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point sticking therapy
Trial: 23140031
Drug: Rectal Balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal Balloon Training (RBT)
Trial: 18537189
Drug: Entecavir 1
RxNorm normalized name: entecavir 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1 mg
Trial: 17983800
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg
Trial: 7720152
Drug: Low-dose midazolam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose midazolam (0.03 mg.kg-1)
Trial: 7720152
Drug: High-dose midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose midazolam (0.06 mg.kg-1)
Trial: 6103906
Drug: Fenoterol hydrobromide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol hydrobromide, 1 mg/ml, nasal spray (204 to 576 microgram)
Trial: 25542917
Drug: Taste receptor
RxNorm normalized name: 60 Second Taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taste receptor genotype
Trial: 23576518
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) group intervention, 8 weeks duration
Trial: 18334911
Drug: Haloperidol 15
RxNorm normalized name: haloperidol 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 15 mg/d
Trial: 14709949
Drug: Thioridazine 300
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine 300 mg/d
Trial: 14709949
Drug: Quetiapine 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 750 mg/d
Trial: 19440083
Drug: Olanzapine 20
RxNorm normalized name: olanzapine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 20 mg/d
Trial: 14709949
Drug: Risperidone 6-8
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6-8 mg/d increased to 16 mg/d
Trial: 14709949
Drug: Metabolic inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic inhibition (concomitant administration of CYP450 inhibitors)
Trial: 2961818
Drug: Plasma-derived vaccine
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived vaccine (40-micrograms dose)
Trial: 2961818
Drug: Recombinant-derived vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant-derived vaccine (40-micrograms and 20-micrograms doses)
Trial: 26258145
Drug: Ramosetron 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.6 mg (group C)
Trial: 26258145
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg (group A)
Trial: 9387643
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide pulse therapy every 2 weeks (15 mg/kg per pulse)
Trial: 9387643
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide pulse therapy every 4 weeks (15 mg/kg per pulse)
Trial: 6374280
Drug: Nifedipine 40
RxNorm normalized name: nifedipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 40 mg oral dose
Trial: 6374280
Drug: Nifedipine 40
RxNorm normalized name: nifedipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 40 mg oral dose with standard breakfast
Trial: 25390695
Drug: Levosimendan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (25 hours infusion)
Trial: 23075178
Drug: Ustekinumab 1
RxNorm normalized name: ustekinumab 130 MG in 26 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 1 mg/kg
Trial: 23075178
Drug: Ustekinumab 3
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab 3 mg/kg
Trial: 29726939
Drug: Ustekinumab 6
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab 6 mg/kg
Trial: 23075178
Drug: Ustekinumab (maintenance)
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab (maintenance) 90 mg
Trial: 20156909
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medroxyprogesterone (500 mg/day) or megestrol acetate (320 mg/day), oral supplementation with eicosapentaenoic acid, L-carnitine (4 g/day), thalidomide (200 mg/day)
Trial: 20156909
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg/day)
Trial: 20156909
Drug: L-carnitine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (4 g/day)
Trial: 20156909
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with eicosapentaenoic acid
Trial: 20156909
Drug: Medroxyprogesterone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone (500 mg/day) or Megestrol acetate (320 mg/day)
Trial: 17360171
Drug: Zileuton 600
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 600 mg QID + 200 microg beclomethasone dipropionate (BDP) BID
Trial: 17360171
Drug: Zileuton 400
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zileuton 400 mg QID + 200 microg beclomethasone dipropionate (BDP) BID
Trial: 16352931
Drug: Goserelin (GOS)
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin (GOS) 3.6 mg/4 weeks for 2 years
Trial: 7666098
Drug: Standard CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CHOP (full doses every 3 weeks)
Trial: 7666098
Drug: Weekly CHOP
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly CHOP (one-third doses weekly)
Trial: 7666098
Drug: Weekly CHOP
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly CHOP
Trial: 2540245
Drug: S-ACV (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ACV (daily suppressive oral acyclovir)
Trial: 23234420
Drug: Oral random
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral random generation (secondary task loading executive functions)
Trial: 16525576
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral aspirin for 5 days
Trial: 16525576
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg oral aspirin for 5 days
Trial: 16525576
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro aspirin (150 micromol/l)
Trial: 16525576
Drug: NS398 (COX-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS398 (COX-2 inhibitor)
Trial: 16525576
Drug: SB203580 (p38-MAPK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB203580 (p38-MAPK inhibitor)
Trial: 11115036
Drug: 150 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mL/kg per day
Trial: 11115036
Drug: 200 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL/kg per day
Trial: 3490803
Drug: Propofol (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.2 mg kg‐1 body weight, reduced to 1.8 mg kg‐1 with opioids and benzodiazepins)
Trial: 29248753
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (300000 Unit, single intramuscular injection)
Trial: 26689781
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) 300 µg and intravenous patient-controlled analgesia (IV-PCA)
Trial: 19889470
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate (15 mg/day)
Trial: 18794551
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg orally once daily
Trial: 18794551
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg orally once daily
Trial: 15983794
Drug: D1/D2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1/D2 receptor stimulation under TPD conditions (using pergolide)
Trial: 7726426
Drug: Epidural clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural clonidine 4 micrograms/kg + morphine 2 mg (Group CM)
Trial: 7726426
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 50 micrograms/kg (Group M)
Trial: 2285385
Drug: Himega (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Himega (2 g/day or 4 g/day of n‐3 fatty acid)
Trial: 2285385
Drug: Triglyceride-based fish
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride-based fish oil (2 g/day or 4 g/day of n‐3 fatty acid)
Trial: 2285385
Drug: Himega (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Himega (2 g/day of n‐3 fatty acid)
Trial: 15251034
Drug: Fluvoxamine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (75 mg BID)
Trial: 11878519
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of controlled hypotension (CH) and acute normovolaemic haemodilution (ANH) (post‐ANH haematocrit 29%; intraoperative MAP 50 mm Hg)
Trial: 19773371
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg b.i.d.
Trial: 20089558
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg b.i.d. in sarcopenic patients with BMI < 25 kg/m²
Trial: 20089558
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg b.i.d. in non-sarcopenic patients and/or overweight or obese
Trial: 20089558
Drug: Sorafenib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 800 mg/day in sarcopenic male patients with BMI < 25 kg/m²
Trial: 20089558
Drug: Sorafenib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 800 mg/day in male patients above the cut-off for sarcopenia
Trial: 20089558
Drug: Sorafenib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 800 mg/day in male patients with BMI > 25
Trial: 18715214
Drug: Sensor group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor group (SG) - pump therapy with real-time continuous glucose monitoring (CGM)
Trial: 18715214
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - pump therapy and self-monitoring of blood glucose only
Trial: 15757423
Drug: Benazepril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril plus amlodipine (40/10 mg)
Trial: 15757423
Drug: Benazepril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril plus hydrochlorothiazide (40/25 mg)
Trial: 8874241
Drug: Dornase alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dornase alfa (2.5 mg once daily)
Trial: 31902864
Drug: Tryptophan, vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan, vitamin B6, and nicotinamide-containing supplements
Trial: 30081500
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Magnesium (120 mg/day as magnesium aspartate)
Trial: 30081500
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Magnesium
Trial: 17785038
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (ccHRT) with estradiol valerate (E2V) and medroxyprogesterone acetate (MPA)
Trial: 12482211
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg per os, evening assumption)
Trial: 12482211
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg bid per os)
Trial: 7726479
Drug: Cefotiam Hexetil
RxNorm normalized name: Cefotiam hexetil hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotiam Hexetil (CTM) 200 mg bid
Trial: 7726479
Drug: Cefixime (CX)
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime (CX) 200 mg bid
Trial: 15195032
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens (320 mg/die of Permixon) for at least 8 weeks before TURP
Trial: 15195032
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medical treatment before intervention)
Trial: 2601868
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of naproxene + 2 g of rosaprostol
Trial: 2601868
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of naproxene + placebo
Trial: 29020783
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa (Elonva) 100 µg for women younger than 36 years and less than 60 kg; 150 µg for women older than 36 years or heavier than 60 kg, combined with GnRH antagonists.
Trial: 29020783
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa and GnRH antagonists
Trial: 26162813
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Same treatment as Group B but ESWT guided by musculoskeletal sonography
Trial: 19210062
Drug: Repetition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetition of persuasive arguments (seen once or twice)
Trial: 15269144
Drug: BEC2 anti-idiotypic
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BEC2 anti-idiotypic monoclonal antibody vaccine (25-microg dose)
Trial: 15269144
Drug: GD3-lactone-KLH (GD3-L-KLH)
RxNorm normalized name: Irinotecan lactone
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GD3-lactone-KLH (GD3-L-KLH) vaccine
Trial: 15269144
Drug: Overall immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall immunization with either vaccine
Trial: 15269144
Drug: GD3-L-KLH vaccine
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GD3-L-KLH vaccine